CLS Americas and HALO Diagnostics Initiate Prostate Cancer Clinical Study using TRANBERG Focal Laser Ablation System
LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO Diagnostics , a leader in precision diagnostics and image-guided therapies (HALO Dx), today announced a 25-patient clinical study using the TRANBERG™ Thermal Therapy System to perform image-guided focal laser ablation (FLA) of low-to-intermediate risk prostate cancer in patients.
- LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO Diagnostics , a leader in precision diagnostics and image-guided therapies (HALO Dx), today announced a 25-patient clinical study using the TRANBERG™ Thermal Therapy System to perform image-guided focal laser ablation (FLA) of low-to-intermediate risk prostate cancer in patients.
- The CLS TRANBERG System provides safe and effective focal laser ablation of low-to-medium risk prostate tumors, while also preserving healthy tissue to minimize the risk of unwanted side effects such as ED and urinary incontinence.
- “CLS is pleased to collaborate with Dr. Scionti and HALO Diagnostics for this clinically significant study regarding the efficacy of treating prostate cancer using image-guided focal laser ablation in an ASC,” stated Michael Magnani, president of CLS Americas.
- “HALO Diagnostic is excited to begin this clinically significant study with CLS Americas and to begin offering this safe and minimally invasive procedure with the new TRANBERG laser through our network.”